• Clinical Insights: May 16, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Retacrit® (epoetin alfa-epbx) – New Biosimilar Drug Approval – May 15, 2018 – U.S. Food and Drug Administration approved Retacrit®(epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin… Read more »

  • Comprehensive Solutions for Your FQHC

    According to NACHC, “community health centers serve as the primary medical home for more than 27 million people in 10,400 rural and urban communities across America.” Just one form of Federally Qualified Health Centers (FQHC), community health centers receive funds from the HRSA Health Center Program to support and serve underserved areas (HRSA). The number… Read more »

  • Clinical Insights: May 9, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Plenvu® (polyethylene glycol 3350 with electrolytes) – May 7, 2018 – Salix Pharmaceuticals, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Plenvu®… Read more »

  • Clinical Insights: May 1, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval JynarqueTM (tolvaptan) – April 24, 2018 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved JynarqueTM (tolvaptan) as… Read more »

  • Clinical Insights: April 23, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Crysvita® (burosumab-twza) – New Orphan Drug Approval – April 17, 2018 – U.S. Food and Drug Administration approved Crysvita® (burosumab-twza), the first drug approved to treat adults… Read more »

  • Connect with Us at the CPS Annual Meeting & Vendor Expo

    May 2-4, Vice President – Implementations and Sales Support Ryen Brumbeloe and Sales Manager ­– Midwest Region Todd Hudnall will attend and exhibit at the Comprehensive Pharmacy Systems/Pharmacy Systems, Inc. (CPS) Annual Meeting & Vendor Expo in Indianapolis, IN. There, over 450 pharmacy decision makers will connect and gain insight into the latest industry news.… Read more »

  • Clinical Insights: April 16, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Formulation Approval Afinitor Disperz® (everolimus) – New Formulation and Indication Approval – April 10, 2018 – On April 10, 2018, the Food… Read more »

  • Ready to Network at the HCP 2018 Spring Hospital Pharmacy Conference

    Justin Rolling and Rhodie Smith are attending the Health Connect Partners (HCP) 2018 Spring Hospital Pharmacy Conference April 30 – May 2 in Atlanta and representing RxStrategies. Here, America’s most prestigious hospitals and health systems will come together to gain industry-leading insight and education and network through the two Reverse EXPO sessions. Be sure to… Read more »

  • Stay on Top of 340B with Split Billing

    RxStrategies recognizes the complexities of 340B program management and offers solutions to better ensure proper management and program compliance. With our Split Billing Solution, you can: Review prescription activity Flag eligible 340B dispenses Designate activity for proper replenishment Audit and report GPO, WAC and 340B With customized reporting, onsite audit support, order confirmations, pharmacy system… Read more »

  • Clinical Insights: April 3, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval SymfiTM (efavirenz, lamivudine and tenofovir disoproxil fumarate) – March 22, 2018 – Mylan N.V. announced that it will introduce in the U.S. a third cost-saving HIV… Read more »